Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of ZENOAQ.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
ZENOAQ
japan Flag
Country
Country
Japan
Address
Address
3rd Floor Surugadai Building, 1-2-5 Kandasurugadai, Chiyoda-Ku, Tokyo 101-0062
Telephone
Telephone
+81-3-5282-2485
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Rituxan is an anti-CD20 monoclonal antibody that specifically binds to CD20. Clinical development of Rituxan for systemic sclerosis was conducted as an investigator-initiated phase II clinical trial (IDEC-C2B).


Lead Product(s): Rituximab

Therapeutic Area: Immunology Product Name: Rituxan

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Chugai Pharmaceutical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 27, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY